Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
McKesson
Medtronic
Cipla
Johnson and Johnson
Express Scripts
Federal Trade Commission
Teva
Daiichi Sankyo
Cerilliant

Generated: October 20, 2017

DrugPatentWatch Database Preview

Allergan Company Profile

« Back to Dashboard

What is the competitive landscape for ALLERGAN, and when can generic versions of ALLERGAN drugs launch?

ALLERGAN has one hundred and one approved drugs.

There are one hundred and twenty US patents protecting ALLERGAN drugs on ALLERGAN drugs in the past three years.

There are eight hundred and ten patent family members on ALLERGAN drugs in forty-four countries and ninety-one supplementary protection certificates in twelve countries.

Summary for Applicant: Allergan

International Patents:810
US Patents:120
Tradenames:86
Ingredients:64
NDAs:101
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
RESTASIS
cyclosporine
EMULSION;OPHTHALMIC050790-001Dec 23, 2002RXYesYes► Subscribe► Subscribe ► Subscribe
Allergan
ALPHAGAN
brimonidine tartrate
SOLUTION/DROPS;OPHTHALMIC020613-001Sep 6, 1996DISCNYesNo► Subscribe► Subscribe► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYesYes► Subscribe► Subscribe ► Subscribe
Allergan Sales Llc
SAVELLA
milnacipran hydrochloride
TABLET;ORAL022256-001Jan 14, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
Allergan Sales Llc
RAPAFLO
silodosin
CAPSULE;ORAL022206-002Oct 8, 2008ABRXYesNo► Subscribe► SubscribeYY ► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-002May 27, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan Sales Llc
OXYTROL FOR WOMEN
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 2013OTCYesYes► Subscribe► SubscribeY ► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYesYes► Subscribe► SubscribeYY ► Subscribe
Allergan Sales Llc
KADIAN
morphine sulfate
CAPSULE, EXTENDED RELEASE;ORAL020616-009Jul 9, 2012ABRXYesNo► Subscribe► Subscribe► Subscribe
Allergan
ACULAR LS
ketorolac tromethamine
SOLUTION/DROPS;OPHTHALMIC021528-001May 30, 2003ATRXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Allergan

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc
KADIAN
morphine sulfate
CAPSULE, EXTENDED RELEASE;ORAL020616-004Mar 9, 2001► Subscribe► Subscribe
Allergan Sales Llc
RAPAFLO
silodosin
CAPSULE;ORAL022206-002Oct 8, 2008► Subscribe► Subscribe
Allergan Sales Llc
TRELSTAR
triptorelin pamoate
INJECTABLE;INTRAMUSCULAR020715-001Jun 15, 2000► Subscribe► Subscribe
Allergan Sales Llc
ALORA
estradiol
FILM, EXTENDED RELEASE;TRANSDERMAL020655-002Dec 20, 1996► Subscribe► Subscribe
Allergan Sales Llc
DILACOR XR
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020092-002May 29, 1992► Subscribe► Subscribe
Allergan
TAZORAC
tazarotene
GEL;TOPICAL020600-002Jun 13, 1997► Subscribe► Subscribe
Allergan
LASTACAFT
alcaftadine
SOLUTION/DROPS;OPHTHALMIC022134-001Jul 28, 2010► Subscribe► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010► Subscribe► Subscribe
Allergan Sales Llc
TRELSTAR
triptorelin pamoate
INJECTABLE;INTRAMUSCULAR021288-001Jun 29, 2001► Subscribe► Subscribe
Allergan
ALPHAGAN
brimonidine tartrate
SOLUTION/DROPS;OPHTHALMIC020613-001Sep 6, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ALLERGAN drugs

Drugname Dosage Strength Tradename Submissiondate
dapsone
Gel7.5%
ACZONE
2/13/2017
alcaftadine
Ophthalmic Solution0.25%
LASTACAFT
7/30/2014
oxybutynin chloride
Gel10%
GELNIQUE
6/19/2014
milnacipran hydrochloride
Tablets12.5 mg, 25 mg, 50 mg, and 100 mg
SAVELLA
1/14/2013
silodosin
Capsules4 mg and 8 mg
RAPAFLO
10/9/2012
ketorolac tromethamine
Opthalmic Solution0.45%
ACUVAIL
8/24/2011
ketorolac tromethamine
Opthalmic Solution0.45%
ACUVAIL
8/23/2011
bimatoprost
Ophthalmic Solution0.01%
LUMIGAN
4/5/2011
gatifloxacin
Ophthalmic Solution0.5%
ZYMAXID
12/7/2010
bimatopros
Topical Solution0.03%
LATISSE
5/3/2010
trospium chloride
Extended-release Capsules60 mg
SANCTURA XR
3/2/2009
bimatoprost
Ophthalmic Solution0.03%
LUMIGAN
12/22/2008
brimonidine tartrate and timolol maleate
Ophthalmic Solution0.2%/0.5%
COMBIGAN
11/21/2008
epinastine hydrochloride
Ophthalmic Solution0.05%
ELESTAT
10/14/2008
oxybutynin
Transdermal System Extended-re3.9 mg/24 hrs
OXYTROL
8/19/2008
gatifloxacin
Ophthalmic Solution0.30%
ZYMAR
7/19/2007
brimonidine tartrate
Ophthalmic Solution0.10%
ALPHAGAN P
12/20/2006
brimonidine tartrate
Ophthalmic Solution0.15%
ALPHAGAN P
11/3/2006
ketorolac tromethamine
Ophthalmic Solution0.40%
ACULAR LS
1/28/2005

Premature patent expirations for ALLERGAN

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Allergan

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,387,788Pharmaceutical compositions of nicotine and methods of use thereof► Subscribe
7,087,241Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy► Subscribe
8,618,064Methods of providing therapeutic effects using cyclosporin components► Subscribe
8,859,604Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid► Subscribe
8,980,309Transdermal testosterone formulation for minimizing skin residues► Subscribe
8,828,446Method for reducing transplant rejection in the eye and intraocular implants for use therefor► Subscribe
7,846,468Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor► Subscribe
7,388,029Compositions and methods for treating hair loss using non-naturally occurring prostaglandins► Subscribe
7,915,246Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain► Subscribe
8,877,793Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using .alpha..sub.1-adrenoceptor agonists► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Allergan Drugs

Country Document Number Estimated Expiration
South Korea101560429► Subscribe
Hong Kong1083684► Subscribe
World Intellectual Property Organization (WIPO)2012075319► Subscribe
South Korea20070015179► Subscribe
MexicoPA06012301► Subscribe
South Korea20050099008► Subscribe
Australia4261097► Subscribe
Australia2005246995► Subscribe
European Patent Office1325752► Subscribe
Japan2013523829► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Allergan Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0443983/03Switzerland► SubscribePRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
C/GB09/026United Kingdom► SubscribePRODUCT NAME: ESTRADIOL AND COMBINATIONS OF ESTRADIOL AND DIENOGEST, PREFERABLY ESTRADIOL VALERATE AND COMBINATIONS OF ESTRADIOL VALERATE AND DIENOGEST; REGISTERED: BE BE 327792 20081103; UK PL 00010/0576-0001 20081208
2017000010Germany► SubscribePRODUCT NAME: ELUXADOLIN; REGISTRATION NO/DATE: EU/1/16/1126 20160919
00099Netherlands► SubscribePRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
C0005Belgium► SubscribePRODUCT NAME: ESTRADIOL HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: 298 IS 190 F 15 19960806; FIRST REGISTRATION: GB PL/0053/0241 19950711
C0033France► SubscribePRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
C/GB98/031United Kingdom► SubscribePRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412
C/GB97/085United Kingdom► SubscribePRODUCT NAME: LEVOFLOXACIN, OPTIONALLY IN THE FORM OF A HEMIHYDRATE; REGISTERED: UK 13402/0011 19970606; UK 13402/0012 19970606; UK 13402/0013 19970606
923Luxembourg► SubscribePRODUCT NAME: UNE SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION: 20150730
2017005Lithuania► SubscribePRODUCT NAME: ELUKSADOLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINAS ENANTIOMERAS, DIASTEREOMERAS, RACEMATAS ARBA DRUSKA; REGISTRATION NO/DATE: EU/1/16/1126 20160919
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Citi
Mallinckrodt
Deloitte
Colorcon
UBS
Cerilliant
Chinese Patent Office
Boehringer Ingelheim
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot